Milana A. Bergamino
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Fatty acids and breast cancer: Epidemiology, subtype-specific metabolism, immune regulation, and clinical translation.
Journal: Molecular and cellular endocrinology
Published: March 27, 2026
Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 11, 2026
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.
Journal: NPJ breast cancer
Published: September 15, 2025
A translational journey into resistance: decoding the role of NF1 in CDK4/6-inhibitor failure.
Journal: EBioMedicine
Published: July 08, 2025
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 20, 2025
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.
Journal: Clinical and translational medicine
Published: May 20, 2025
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Journal: International journal of molecular sciences
Published: September 17, 2024
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 30, 2024
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.
Journal: Therapeutic advances in medical oncology
Published: July 13, 2024
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: August 07, 2023
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Journal: EBioMedicine
Published: February 18, 2022
Last Updated: 09/26/2026